S
FDMT icon

SignatureFD’s 4D Molecular Therapeutics FDMT Stock Holding History

SignatureFD’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-614
Closed -$3.42K – 3356
2024
Q4 		$3.42K Buy
614
+73
+13% +$573 ﹤0.01% 2722
2024
Q3 		$5.85K Sell
541
-27
-5% -$448 ﹤0.01% 2524
2024
Q2 		$11.9K Sell
568
-33
-5% -$828 ﹤0.01% 2195
2024
Q1 		$19.1K Buy
601
+22
+4% +$561 ﹤0.01% 2016
2023
Q4 		$11.7K Buy
+579
New +$7.62K ﹤0.01% 2188
2023
Q3 		– Sell
-22
Closed -$398 – 3231
2023
Q2 		$398 Buy
+22
New +$405 ﹤0.01% 3088
2023
Q1 		– Sell
-30
Closed -$666 – 3315
2022
Q4 		$666 Sell
30
-36
-55% -$556 ﹤0.01% 3057
2022
Q3 		$1K Buy
+66
New +$598 ﹤0.01% 2953
2022
Q2 		– Sell
-45
Closed -$1K – 3175
2022
Q1 		$1K Sell
45
-75
-63% -$1.18K ﹤0.01% 2978
2021
Q4 		$3K Sell
120
-60
-33% -$1.47K ﹤0.01% 2577
2021
Q3 		$5K Buy
180
+94
+109% +$2.68K ﹤0.01% 2339
2021
Q2 		$2K Buy
+86
New +$2.63K ﹤0.01% 2569

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SignatureFD's FDMT Position: Q1 2025 in Review

SignatureFD sold out of 4D Molecular Therapeutics (FDMT) in Q1 2025, closing a stake of 614 shares — an estimated $3.42K sold.

SignatureFD first reported a position in FDMT in Q2 2021 and held it in 12 quarters. The position peaked at $19.1K in Q1 2024. 125 funds tracked by Wall St. Rank hold FDMT as of Q1 2025.

  • SignatureFD reported no remaining 4D Molecular Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SignatureFD sold 614 4D Molecular Therapeutics shares in Q1 2025, an estimated $3.42K.
  • SignatureFD first reported a position in 4D Molecular Therapeutics in Q2 2021 and held it in 12 quarters.
  • SignatureFD's 4D Molecular Therapeutics position peaked at $19.1K in Q1 2024.
  • 125 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2025.

Based on SignatureFD's 13F filing for Q1 2025, filed 2 May 2025.